A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database

Authors: Jie Li, Jun Xie, Yi Han, Wei Zhang, Yilei Wang, Zhitao Jiang

Source: Endocrine Journal, Vol 72, Iss 3, Pp 273-283 (2025)

Subject Terms: tirzepatide, gip/glp-1 ra, disproportionality analysis, fda adverse event reporting system (faers), adverse drug event, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

File Description: electronic resource

Relation: https://www.jstage.jst.go.jp/article/endocrj/72/3/72_EJ24-0286/_html/-char/en; https://doaj.org/toc/1348-4540

Access URL: https://doaj.org/article/78d547c8fec2400ca3c7ef9aebbb9547

Investigating Drug-Induced Thyroid Dysfunction Adverse Events Associated With Non-Selective RET Multi-Kinase Inhibitors: A Pharmacovigilance Analysis Utilizing FDA Adverse Event Reporting System Data

Authors: Meng Z, Song L, Wang S, Duan G

Source: Clinical Epidemiology, Vol Volume 17, Pp 87-104 (2025)

Subject Terms: drug-induced thyroid dysfunction, non-selective ret mkis, pharmacovigilance, fda adverse event reporting system, clinical monitoring., Infectious and parasitic diseases, RC109-216

File Description: electronic resource

Relation: https://www.dovepress.com/investigating-drug-induced-thyroid-dysfunction-adverse-events-associat-peer-reviewed-fulltext-article-CLEP; https://doaj.org/toc/1179-1349

Access URL: https://doaj.org/article/f10efae685704a488c866e23a0fefde2

A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system

Authors: Yong Yu, Xin Sun, Liqun Hao, Xiaoyan Zhang, Yankui Guo

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-9 (2025)

Subject Terms: Trazodone, FDA adverse event reporting system, Adverse drug reaction, Data mining, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/1a7e6aaebe5447cfa65f1d4d977ccf35

Adverse events in the nervous system associated with blinatumomab: a real-world study

Authors: Wen Gao, Jingwei Yu, Yifei Sun, Zheng Song, Xia Liu, Xue Han, Lanfan Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

Source: BMC Medicine, Vol 23, Iss 1, Pp 1-12 (2025)

Subject Terms: Blinatumomab, Nervous system toxicity, Pharmacovigilance, FDA Adverse Event Reporting System (FAERS), Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1741-7015

Access URL: https://doaj.org/article/ea8c5f72e3944b5ba2f31de24c9b8204

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Authors: Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Source: BMC Cancer, Vol 25, Iss 1, Pp 1-9 (2025)

Subject Terms: FDA adverse event reporting system, Non-small cell lung cancer, Immune checkpoint inhibitor, Immune-related adverse event, Pharmacovigilance signal, Matrix of pairwise comparison, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/f3d5e9cb57fe46fda40942cc4430279d

Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS

Authors: Zhaojun Wang, Xin Su, Donglei Shi, Li Wei

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)

Subject Terms: Zoledronic acid, FDA adverse event reporting system, Adverse events, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/329afb91268745a9a00c6c4f2a14c7b7

Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system

Authors: Yankun Liang, Zhenpo Zhang, Jingping Zheng, Yuting Wang, Jiaxin He, Juanzhi Zhao, Ling Su

Source: Endocrine Connections, Vol 13, Iss 12, Pp 1-10 (2024)

Subject Terms: cholecystitis cholelithiasis, dipeptidyl peptidase-4 inhibitors, fda adverse event reporting system, glucagonlike peptide-1 receptor agonists, hepatobiliary adverse events, incretin-based therapies, type 2 diabetes mellitus, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

File Description: electronic resource

Relation: https://ec.bioscientifica.com/view/journals/ec/13/12/EC-24-0404.xml; https://doaj.org/toc/2049-3614

Access URL: https://doaj.org/article/6d73d621ce374d4eb5999ecb8e5d8476

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors

Authors: Yuhui Yang, Pingping Long, Ying Tuo, Xiaoxiao Wang

Source: Frontiers in Immunology, Vol 16 (2025)

Subject Terms: immune checkpoint inhibitors, angiogenesis inhibitors, FDA adverse event reporting system (FAERS), hemorrhagic risks, cancer therapy, immunotherapy, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1527570/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/2986da899f194dd4902d7c53b1d49ba5

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network

Authors: Yang Gao, Xiang Zhang, Zhongquan Sun, Payal Chandak, Jiajun Bu, Haishuai Wang

Source: Advanced Science, Vol 12, Iss 4, Pp n/a-n/a (2025)

Subject Terms: adverse drug reactions, FDA adverse event reporting system (FAERS), graph neural network, precision medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2198-3844

Access URL: https://doaj.org/article/d4e5516fe05b43dda2fe363ffe946f25

Subgroup disproportionality analysis of dementia-related adverse events with sacubitril/valsartan across geographical regions

Authors: Seong Kyung Kim, Myeong Gyu Kim

Source: Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)

Subject Terms: Sacubitril/valsartan, Dementia, FDA adverse event reporting system, Geographic location, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0

Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database

Authors: Hyo Jung Kim, Jeong-Hwa Yoon, Yeon Hee Park

Source: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)

Subject Terms: Pharmacovigilance, Post-marketing surveillance, FDA Adverse Event Reporting System, Real-world data, Hepatobiliary disorder, Trastuzumab emtansine, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/cf8ea2b8612645708a91c061907a0d54

Real-world safety profile of direct oral anticoagulants (DOACs): Disproportionality analysis of major bleeding events

Authors: di Biase, Lazzaro ^{a, c, ⁎}, Bonura, Adriano ^{a, b}, Pecoraro, Pasquale Maria ^{a, b}, Di Lazzaro, Vincenzo ^{a, b}

Source: In Journal of Stroke and Cerebrovascular Diseases February 2025 34(2)

Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases

Authors: Chunsu Liang, Pengjiao An, Yizhou Zhang, Xin Liu, Bo Zhang

Source: Frontiers in Immunology, Vol 15 (2024)

Subject Terms: drug reaction with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome, FDA adverse event reporting system, fatal cases, drug adverse reaction, systematic review, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490334/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/f44d43cc7c94458db57345c6bcb73507

Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004–2023)

Authors: Xiao-Dong Chen, Kun-Hong Xiao, Chao-Bing Zhou

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: retinal vein occlusion, FDA adverse event reporting system, disproportionality analysis, pharmacovigilance, adverse events, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1480269/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/e061c4e571c94c8c99d46e2c48f989c9

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib

Authors: Yi Yin, Fengli Sun, Youpeng Jin

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: FDA Adverse Event Reporting System (FAERS), pralsetinib, pharmacovigilance, real-world analysis, adverse event (AE), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1491167/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/b370a1dfd9c8400b88880881b9190b94

Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis

Authors: Yuanqiong Duan, Ying Wang, Shentao Lu, Mei Zeng, Lubin Liu, Qian Dai, Rutie Yin

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: albumin-bound paclitaxel, adverse drug events, FDA adverse event reporting system, signal mining, pharmacovigilance analysis, real-world study, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1448144/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/bf3d92cde70348f183ff0f131c49423f

Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system

Authors: Yifeng Bai, Xiaomei Wang, Xiaoqin Dai, Qinghua Ma, Honglin Hu

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: SCLC, FDA adverse event reporting system (FAERS), ICIs, immune check point inhibitors, irAEs (immune-related adverse events), adverse (side) effects, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1398667/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/5ae4c212c0f64944b6212f9b26ad5e1c

Assessing the safety of midazolam: A comprehensive analysis of adverse events from FAERS

Authors: Chen, Jieyuan ^{a, 1}, Wang, Zhaojun ^{b, 1}, Wei, Li ^{b, ⁎}, Mao, Songsong ^{a, ⁎}

Source: In Toxicology in Vitro May 2025 105

The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database

Authors: Zheng, Yu ^a, Gao, Xiao-Jing ^a, Huang, Ji-Jun ^b, Chen, Xiang-Ming ^b, Liao, Yue ^b, Liu, Jia-Min ^b, Zheng, Yan-Ling ^b, Zhao, Yu-Yang ^b, Ding, Rui-Lian ^{a, d}, Li, Xiao-Min ^b, Bu, Jin ^{a, ⁎}, Shen, Er-Xia ^{b, c, ⁎⁎}

Source: In International Immunopharmacology 4 April 2025 151

Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System

Authors: Hilal A. Thaibah, Otilia J. F. Banji, David Banji, Thamir M. Alshammari

Source: Pharmaceuticals, Vol 18, Iss 2, p 214 (2025)

Subject Terms: diabetic ketoacidosis (DKA), FDA adverse event reporting system (FAERS), hypoglycemic agents, real-world evidence (RWE), SGLT2 inhibitors, Medicine, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://www.mdpi.com/1424-8247/18/2/214; https://doaj.org/toc/1424-8247

Access URL: https://doaj.org/article/183d65e48f3b41d7aef26bd7dae6e1e8